Utility of Continuous Metabolic Syndrome Score in Assessing Risk of Type 2 @entity6 : The Isfahan XXXX Prevention Study.

@entity1 @entity2175 @entity6 @entity209 @entity413 @entity165
BACKGROUND/AIM: It is not clear whether levels of continuous @entity209 (cMetS) are associated with @entity2175 ( @entity2175 ). The aim of this study was to determine the ability of the cMetS score to predict progression to @entity2175 in non-diabetic first-degree relatives (FDRs) of @entity1 with @entity2175 in Isfahan, Iran. METHODS: A total of 1,869 non-diabetic FDRs 30-70 years old in 2003-2005 were followed through 2014 for the occurrence of @entity2175 . At baseline and through follow-ups, @entity1 underwent a standard 75 g 2-h oral @entity413 tolerance test. MetS was defined by the National @entity165 Education Program-Adult Treatment Panel III. The cMetS score was calculated using age- and gender-standardized Z-score for MetS components. Receiver operating characteristic (ROC) curve was used to assess the association between cMetS and components of MetS with @entity2175 . RESULTS: During 13,571 @entity1 -years of follow-up, 72 @entity1 and 210 @entity1 developed @entity6 . Those in the top quartile of cMetS were 8.0 times more likely to develop @entity6 than those in the bottom quartile (OR 7.96; 95% CI 4.88-12.99). On ROC curve analysis, a higher area under the ROC were found for FPG (74.3%; 95% CI 70.8-77.8), than for cMetS (69.4%; 95% CI 66.0-72.8). CONCLUSIONS: The cMetS score is a robust predictor of @entity2175 and may be more effective and efficient than the current binary definition of MetS in predicting progression to @entity2175 in our study population.
